The role of mullerian inhibiting substance in female reproduction

Current Opinion in Obstetrics and Gynecology

Volumn 20, Issue 3, 2008, Pages 257-264

  Nakhuda, Gary S ^a  

^a Center for Women's Reproductive Care ^*  (United States)

Author keywords

Anti mullerian hormone; In vitro fertilization; Mullerian inhibiting substance; Ovarian reserve; Polycystic ovary syndrome

Indexed keywords

AROMATASE; FOLLITROPIN; MUELLERIAN INHIBITING FACTOR;

AMENORRHEA; ANOVULATION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENDOMETRIOSIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FERTILIZATION IN VITRO; HORMONE DETERMINATION; HUMAN; HYPERANDROGENISM; INFERTILITY THERAPY; INSULIN RESISTANCE; MEDICAL PARAMETERS; MENSTRUAL CYCLE; NONHUMAN; OBESITY; OVARY FOLLICLE; OVARY FOLLICLE FLUID; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INTERACTION; REPRODUCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; FEMALE; FERTILIZATION IN VITRO; HUMANS; INFERTILITY, FEMALE; OOCYTES; POLYCYSTIC OVARY SYNDROME;

EID: 43149095105     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282fe99f2     Document Type: Review

References (67)

1. Jost A. Research on the sexual differentiation in rabbit embryos [in French]. Arch Anat Micros Morphol Exp 1947; 36:271-315.
2. Josso N. In vitro synthesis of mullerian-inhibiting hormone by seminiferous tubules isolated from the calf fetal testis. Endocrinology 1973; 93:829-834.
3. Gustafson ML. Mullerian inhibiting substance in the diagnosis and management of intersex and gonadal abnormalities. J Pediatr Surg 1993; 28:439-444.
4. Seifer DB. Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid mullerian-inhibiting substance and androgen content. J Clin Endocrinol Metab 1993; 76:711-714.
5. Al-Qahtani A, Groome NP. Editorial: anti-mullerian hormone: Cinderella finds new admirers. J Clin Endocrinol Metab 2006; 91:3760-3762.
6. Hehenkamp WJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006; 91:4057-4063.
7. Freour T. Measurement of serum anti-Mullerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta 2007; 375 (1-2):162-164. This article and the one by Bersinger et al. [11] compare the two commercially available MIS assays.
8. Merhi ZO, Messerlian GM, Minkoff H, et al. Comparison of serum and plasma measurements of Mullerian inhibiting substance. Fertil Steril 2007; [Epub ahead of print].
9. Pellatt L. Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007; 92:240-245.
10. Andersen CY, Lossl K. Increased intrafollicular androgen levels affect human granulosa cell secretion of antimullerian hormone and inhibin-B. Fertil Steril 2007 [Epub ahead of print].
11. Bersinger NA, Wunder D, Birkhauser MH, Guibourdenche J. Measurement of antimullerian hormone by Beckman Coulter ELISA and DSL ELISA in assisted reproduction: differences between serum and follicular fluid. Clin Chim Acta 2007; 384:174-175.
12. Cohen-Haguenauer O. Mapping of the gene for antimullerian hormone to the short arm of human chromosome 19. Cytogenet Cell Genet 1987; 44:2-6.
13. Josso N, Clemente N. Transduction pathway of anti-Mullerian hormone, a sex-specific member of the TGF-beta family. Trends Endocrinol Metab 2003; 14:91-97.
14. Kevenaar ME. Anti-Mullerian hormone and anti-Mullerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Hum Reprod 2007; 22:1547-1554. The two articles by Kevenaar take a genetic approach to investigating the role of MIS in reproductive aging and reveal a possible polymorphism that may be associated with follicular phase estradiol levels in normo-ovulatory women.
15. Kevenaar ME. A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity. Hum Reprod 2007; 22:2382-2388.
16. Grossman MP, Nakajima ST, Fallat ME, Siow Y. Mullerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil Steril 2007 [Epub ahead of print].
17. di Clemente N. A quantitative and interspecific test for biological activity of antimullerian hormone: the fetal ovary aromatase assay. Development 1992; 114:721-727.
18. Wachs DS. Serum antimullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J Clin Endocrinol Metab 2007; 92:1871-1874. A classic endocrine approach to studying the pattern of MIS secretion subsequent to a bolus of FSH administration.
19. Durlinger AL. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001; 142:4891-4899.
20. Durlinger AL. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999; 140:5789-5796.
21. Weenen C. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004; 10:77-83.
22. Fanchin R. Coordination of antral follicle growth: basis for innovative concepts of controlled ovarian hyperstimulation. Semin Reprod Med 2005; 23:354-362.
23. La Marca A. Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 2004; 19:2738-2741.
24. Tsepelidis S. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod 2007; 22:1837-1840.
25. Cook CL. Serum mullerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril 2000; 73:859-861.
26. La Marca A, Volpe A. AntiMullerian serum levels during pregnancy. Clin Endocrinol (Oxf) 2006; 64:715-716.
27. Streuli I, Fraisse T, Pillet C, et al. Serum antimullerian hormone levels remain stable throughout the mestrual cycle and after oral and vaginal administration of synthetic sex steroids. Fertil Steril 2007 [Epub ahead of print].
28. Wunder D, Bersinger N, Yared M, et al. Statistically significant changes of antimullerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril 2007 [Epub ahead of print]. One of the few studies indicating that serum MIS levels do indeed significantly vary over the course of the menstrual cycle.
29. Fanchin R. Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 2003; 18:328-332.
30. Wang JG, Nakhuda GS, Guarnaccia MM, et al. Mullerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome. Am J Obstet Gynecol 2007; 196:77.e1-77.e5.
31. Arbo E. Serum antimullerian hormone levels and follicular cohort characteristics after pituitary suppression in the late luteal phase with oral contraceptive pills. Hum Reprod 2007; 22:3192-3196.
32. Baarends WM. Antimullerian hormone and antimullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology 1995; 136:4951-4962.
33. Catteau-Jonard S. Changes in serum antimullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:4138-4143.
34. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41-47.
35. Fallat ME. Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril 1997; 67:962-965.
36. Pigny P. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:941-945.
37. Crisosto N, Codner E, Maliqueo M, et al. Anti-Mullerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:2739-2743.
38. Fleming R. Dynamics of FSH-induced follicular growth in subfertile women: relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone. Hum Reprod 2006; 21:1436-1441.
39. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2007; 134:196-201.
40. Cook CL. Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril 2002; 77:141-146.
41. La Marca A. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004; 82:970-972.
42. Laven JS. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89:318-323.
43. Piltonen T. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005; 20:1820-1826.
44. Futterweit W, Yeh HC, Mechanick JI. Ultrasonographic study of ovaries of 19 women with weight loss-related hypothalamic oligo-amenorrhea. Biomed Pharmacother 1988; 42:279-283.
45. Jonard S. The ovarian markers of the FSH insufficiency in functional hypothalamic amenorrhoea. Hum Reprod 2005; 20:101-107.
46. Massin N. Significance of ovarian histology in the management of patients presenting a premature ovarian failure. Hum Reprod 2004; 19:2555-2560.
47. Meduri G. Serum anti-Mullerian hormone expression in women with premature ovarian failure. Hum Reprod 2007; 22:117-123.
48. La Marca A. Serum antimullerian hormone levels in women with secondary amenorrhea. Fertil Steril 2006; 85:1547-1549.
49. Lemos NA, Arbo E, Scalco R, et al. Decreased anti-Mullerian hormone and altered ovarian follicular cohort in infertile patients with mild/minimal endometriosis. Fertil Steril 2007 [Epub ahead of print].
50. Spandorfer SD. Obesity and in vitro fertilization: negative influences on outcome. J Reprod Med 2004; 49:973-977.
51. Pigny P. Elevated serum level of antimullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003; 88:5957-5962.
52. Gracia CR. The relationship between obesity and race on inhibin B during the menopause transition. Menopause 2005; 12:559-566.
53. Freeman EW. Association of antimullerian hormone levels with obesity in late reproductive-age women. Fertil Steril 2007; 87:101-106.
54. Seifer DB. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77:468-471.
55. van Rooij IA. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002; 17:3065-3071.
56. Elgindy EA, El-Haieg DO, El-Sebaey A. Anti-Mullerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertil Steril 2007 [Epub ahead of print].
57. Ficicioglu C. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 2006; 85:592-596.
58. Nakhuda GS. Mullerian inhibiting substance is an accurate marker of ovarian response in women of advanced reproductive age undergoing IVF. Reprod Biomed Online 2007; 14:450-454.
59. Kwee J, Schats R, McDonnell J, et al. Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve. Fertil Steril 2007 [Epub ahead of print].
60. Silberstein T. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve andembryo morphology. Hum Reprod 2006; 21:159-163.
61. Ebner T. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 2006; 21:2022-2026.
62. Lekamge DN. Anti-Mullerian hormone as a predictor of IVF outcome. Reprod Biomed Online 2007; 14:602-610.
63. Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod 2007; 22:2414-2421. This study suggests that live birth rates correlate to baseline MIS levels, a conclusion not supported by previous studies.
64. Fraisse T, Ibecheole V, Streuli I, et al. Undetectable serum anti-Mullerian hormone levels and occurrence of ongoing pregnancy. Fertil Steril 2008; 89:723.e9-723.e11.
65. Fanchin R. Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab 2007; 92:1796-1802.
66. Nakhuda GS. Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril 2006; 85:1541-1543.
67. Lee TH. Serum antimullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008; 23:160-167.